WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti in Patients with Late-Onset Pompe Disease

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic

Related Keywords

Wuxi ,Jiangsu ,China ,Singapore ,Germany ,United States ,Ireland ,Chris Chen ,European Commission ,Manufacturing Organization ,Committee For Medicinal Products Human Use ,Contract Research ,Amicus Therapeutics ,Wuxi Biologics ,Wuxi Biologic ,Medicinal Products ,Human Use ,Iologics ,Ongratulates ,Amicus ,Herapeutics ,European ,Commission ,Approval ,Ombiliti ,Patients ,Gate ,Onset ,Pompe ,Disease ,